FIELD: pharmaceutical industry. SUBSTANCE: novel agent improving moisture resistance and reducing influence of permeating moisture on fine fraction of dry inhalation powder represents magnesium stearate. EFFECT: allowed increase of doses of disperse particles and their fine fraction, essentially increased stability of the latter on storage at 40 C and relative humidity 75%. 21 cl, 6 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTIC COMPOSITIONS | 2005 |
|
RU2396943C2 |
| METHOD FOR PRODUCING CARRIER PARTICLES FOR DRY POWDERS FOR INHALATIONS | 2011 |
|
RU2585101C2 |
| METHOD OF PRODUCING A DRY POWDER COMPOSITION CONTAINING AN ANTICHOLINERGIC, CORTICOSTEROID AND BETA-ADRENERGIC AGENT | 2018 |
|
RU2742376C1 |
| METHOD OF PRODUCING A DRY POWDER COMPOSITION CONTAINING AN ANTICHOLINERGIC, CORTICOSTEROID AND BETA-ADRENERGIC AGENT | 2018 |
|
RU2741427C1 |
| INHALATION PHARMACEUTICAL COMPOSITION (VARIANTS) AND METHOD OF ITS PREPARING | 1995 |
|
RU2140260C1 |
| ORGANIC COMPOUNDS | 2008 |
|
RU2482838C2 |
| INHALATION PARTICLES CONTAINING COMBINATION OF ANTICHOLINERGIC, CORTICOSTEROID AND BETA-ADRENERGIC AGENTS | 2015 |
|
RU2697867C2 |
| INHALATION COMPOSITIONS CONTAINING GLYCOPYRRONIUM SALTS | 2007 |
|
RU2453302C2 |
| PHARMACEUTICAL DRUG FORMS CONTAINING LOW-DOSAGE ACTIVE COMPONENT FOR DRY POWDER INHALATORS | 2005 |
|
RU2371171C2 |
| METHOD FOR PRODUCING LOW-STATIC PARTICLES | 2011 |
|
RU2580312C2 |
